A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in ...
Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded access Study achieving primary endpoints of safety, tolerability, and efficacy ...
Hosted on MSN
Recce Pharmaceuticals secures A$85 million R&D tax incentive for global anti-infective programs
Recce Pharmaceuticals Ltd. ( (AU:RCE)) has shared an update. Recce Pharmaceuticals has been awarded an Advanced Overseas Finding for up to A$85 million by the Australian Government, which extends the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results